Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.

Hande KızılocakElizabeth Marquez-CasasJemily MalvarRoxana CarmonaGuy Aaron Young

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

The results from this study suggest that the F8EmT in patients with severe HA on emicizumab falls within the range of mild haemophilia which is consistent with the data noted in the emicizumab clinical trials and in vivo studies in animals.

Keyphrases

clinical trial
early onset
epithelial mesenchymal transition
electronic health record
big data
high throughput
randomized controlled trial
deep learning
open label